Latest filing published 12 Aug 2026 for BeOne Medicines Ltd., €777k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
John Oyler, listed as chief executive, appears in our data through filings on BeOne Medicines Ltd. shares, published by SEC (Form 4). We count 146 filings; the first trade dates from 8 February 2016 and the latest from 12 August 2026.
On the market, this insider has only sold: 120 sales, €275.8M in total. The totals exclude 12 filings filed without an amount. Besides market trades, the filings include 8 share grants and 16 option exercises. In 2026 alone, the filings show no purchases and 97 sales.
The record was last updated on 12 August 2026 with an open-market sale (€856k) in BeOne Medicines Ltd. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 146 declarations